Presentation is loading. Please wait.

Presentation is loading. Please wait.

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model by Beth D. Kirkpatrick, Stephen S. Whitehead,

Published byMette Jespersen Modified over 4 years ago

Similar presentations

Presentation on theme: "The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model by Beth D. Kirkpatrick, Stephen S. Whitehead,"— Presentation transcript:

1 The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model by Beth D. Kirkpatrick, Stephen S. Whitehead, Kristen K. Pierce, Cecilia M. Tibery, Palmtama L. Grier, Noreen A. Hynes, Catherine J. Larsson, Beulah P. Sabundayo, Kawsar R. Talaat, Anna Janiak, Marya P. Carmolli, Catherine J. Luke, Sean A. Diehl, and Anna P. Durbin Sci Transl Med Volume 8(330):330ra36-330ra36 March 16, 2016 Copyright © 2016, American Association for the Advancement of Science

2 Fig. 1. Screening, enrollment, and follow-up of flavivirus-seronegative subjects for vaccination with the dengue vaccine TV003 and challenge with DENV-2 6 months later. Screening, enrollment, and follow-up of flavivirus-seronegative subjects for vaccination with the dengue vaccine TV003 and challenge with DENV-2 6 months later. As described in the text, 48 subjects were randomly assigned to receive TV003 or placebo on study day 0. The treatment assignment was masked to study staff and volunteers. On study day 180, all eligible subjects (41) received the challenge virus rDEN2Δ30. PI, principal investigator. Beth D. Kirkpatrick et al., Sci Transl Med 2016;8:330ra36 Copyright © 2016, American Association for the Advancement of Science

Download ppt "The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model by Beth D. Kirkpatrick, Stephen S. Whitehead,"

Similar presentations

Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates by Gary Wong, Jason S. Richardson, Stéphane.

Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates by Gary Wong, Jason S. Richardson, Stéphane.
Toward Universal Flavivirus Identification by Mass Cataloging

Toward Universal Flavivirus Identification by Mass Cataloging
Targeted DNA vaccination induced protection against nasal challenge with influenza virus 14 d after DNA vaccination. Targeted DNA vaccination induced protection.

Targeted DNA vaccination induced protection against nasal challenge with influenza virus 14 d after DNA vaccination. Targeted DNA vaccination induced protection.
Long-lasting protection against nasal challenge with influenza virus 252 d after a single DNA vaccination. Long-lasting protection against nasal challenge.

Long-lasting protection against nasal challenge with influenza virus 252 d after a single DNA vaccination. Long-lasting protection against nasal challenge.
Dengue Antibody and Zika: Friend or Foe?

Dengue Antibody and Zika: Friend or Foe?
Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.
Fig. 5. Rises in RSV PRNT during the surveillance period.

Fig. 5. Rises in RSV PRNT during the surveillance period.
Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.
Fig. 7 Correlation of NHP and human ISGs.

Fig. 7 Correlation of NHP and human ISGs.
Fig. 4. Peanut-specific TH2A cells are specifically targeted during immunotherapy. Peanut-specific TH2A cells are specifically targeted during immunotherapy.

Fig. 4. Peanut-specific TH2A cells are specifically targeted during immunotherapy. Peanut-specific TH2A cells are specifically targeted during immunotherapy.
Fig. 1 ZIKV RNA in blood and tissues.

Fig. 1 ZIKV RNA in blood and tissues.
Consolidated Standards of Reporting Trials flow diagram of VRC trial

Consolidated Standards of Reporting Trials flow diagram of VRC trial
Fig. 2 Whisker deprivation accelerates and enhances behavioral recovery after right S1FP photothrombosis. Whisker deprivation accelerates and enhances.

Fig. 2 Whisker deprivation accelerates and enhances behavioral recovery after right S1FP photothrombosis. Whisker deprivation accelerates and enhances.
Fig. 1. Loss of circadian rhythms in iKO mice.

Fig. 1. Loss of circadian rhythms in iKO mice.
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Filipin staining of marginal gyrus of cerebral cortex in NPC cats

Filipin staining of marginal gyrus of cerebral cortex in NPC cats
Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.
Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.
Fig. 3. Comparison of prediction performance.

Fig. 3. Comparison of prediction performance.
Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Similar presentations

Ads by Google